成人主动脉瓣新瓣叶成形术(Ozaki手术)的中期结局
本研究比较了成人主动脉瓣新瓣叶成形术(AVN)与生物瓣主动脉瓣置换术(SAVR)的中期结局。2015年至2022年间,101例患者接受AVN,1816例接受SAVR。倾向性评分匹配后每组77例,5年生存率与免于至少中度主动脉瓣反流率在两组间无显著差异(P=.95和P=.23)。
要点
- AVN组无患者需转为SAVR,30天无死亡。
- 匹配后5年生存率两组等效(P=.95),免于至少中度主动脉瓣反流率相当(P=.23)。
- AVN可安全用于多种主动脉瓣疾病,伴或不伴合并手术。
核心结论
- AVN可安全用于多种主动脉瓣疾病,伴或不伴合并手术;在美国成人人群中,AVN与生物瓣SAVR的中期结局相似。
研究设计与样本
- 回顾性队列研究,纳入2015年至2022年间接受AVN或生物瓣SAVR的所有成人患者,使用倾向性评分匹配调整基线特征。
主要发现
- AVN组101例,SAVR组1816例;AVN组无一例需转为SAVR。
- AVN组匹配前平均年龄68.5±8.8岁,56例(55.4%)接受合并手术,术前3例(3%)有心内膜炎,38例(38.4%)有二叶瓣。
- AVN组30天无死亡,中位随访3.2年。
- 倾向性评分匹配后每组77例;5年预期生存率91.7%±3.1%,免于至少中度主动脉瓣反流率97.6%±1.7%。
- 匹配后5年生存率两组等效(P=.95),免于至少中度主动脉瓣反流率相当(P=.23)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trileaflet aortic valve neocuspidization (AVN) using autologous pericardium (Ozaki procedure) is an emerging surgical treatment option for aortic valve diseases. Although excellent results have been reported from Japan, data pertaining to its use in the United States are sparse. METHODS: All adult patients who underwent AVN (AVN group) or surgical aortic valve replacement (SAVR) with a bioprosthetic valve (SAVR group) between 2015 and 2022 were identified. Propensity score matching was used to adjust the baseline characteristics between the 2 groups. RESULTS: A total of 101 patients underwent AVN, and 1816 patients underwent SAVR with a bioprosthetic valve. None in the AVN group required conversion to SAVR. Before matching, mean age in the AVN group was 68.5 ± 8.8 years, and 56 patients (55.4%) underwent concomitant procedures. Preoperatively, 3 (3%) had endocarditis. Bicuspid valve was observed in 38 (38.4%). None died at 30 days in the AVN group. The median follow-up duration was 3.2 years. After propensity score matching, the expected survival and freedom from at least moderate aortic regurgitation at 5 years was 91.7% ± 3.1% and 97.6% ± 1.7%, respectively. Propensity score matching yielded 77 patients in each group. The Kaplan-Meier curve demonstrated equivalent survival at 5 years between the 2 groups (P = .95). Additionally, freedom from at least moderate aortic regurgitation was comparable at 5 years (P = .23). CONCLUSIONS: AVN can be safely performed for a variety of aortic valve diseases, with or without concomitant operations. AVN demonstrated similar midterm outcomes compared with SAVR with a bioprosthetic valve in the United States adult population.
引用
- Ogami T, Dufendach KA, Imran M, et al. Midterm Outcomes After Aortic Valve Neocuspidization (Ozaki Procedure) in Adults. Ann Thorac Surg. 2024. PMID: 38216078. doi:10.1016/j.athoracsur.2023.12.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。